403 related articles for article (PubMed ID: 22428797)
1. Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities.
Waite CL; Roth CM
Crit Rev Biomed Eng; 2012; 40(1):21-41. PubMed ID: 22428797
[TBL] [Abstract][Full Text] [Related]
2. Lipid-enveloped hybrid nanoparticles for drug delivery.
Tan S; Li X; Guo Y; Zhang Z
Nanoscale; 2013 Feb; 5(3):860-72. PubMed ID: 23292080
[TBL] [Abstract][Full Text] [Related]
3. Human solid tumors and clinical relevance of the enhanced permeation and retention effect: a 'golden gate' for nanomedicine in preclinical studies?
Gawali P; Saraswat A; Bhide S; Gupta S; Patel K
Nanomedicine (Lond); 2023 Jan; 18(2):169-190. PubMed ID: 37042320
[TBL] [Abstract][Full Text] [Related]
4. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
Danhier F
J Control Release; 2016 Dec; 244(Pt A):108-121. PubMed ID: 27871992
[TBL] [Abstract][Full Text] [Related]
5. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology.
Prabhakar U; Maeda H; Jain RK; Sevick-Muraca EM; Zamboni W; Farokhzad OC; Barry ST; Gabizon A; Grodzinski P; Blakey DC
Cancer Res; 2013 Apr; 73(8):2412-7. PubMed ID: 23423979
[TBL] [Abstract][Full Text] [Related]
6. Potential drug delivery nanosystems for improving tumor penetration.
Peng F; Li R; Zhang F; Qin L; Ling G; Zhang P
Eur J Pharm Biopharm; 2020 Jun; 151():220-238. PubMed ID: 32311427
[TBL] [Abstract][Full Text] [Related]
7. Tumor heterogeneity and nanoparticle-mediated tumor targeting: the importance of delivery system personalization.
Swetha KL; Roy A
Drug Deliv Transl Res; 2018 Oct; 8(5):1508-1526. PubMed ID: 30128797
[TBL] [Abstract][Full Text] [Related]
8. Size shrinkable drug delivery nanosystems and priming the tumor microenvironment for deep intratumoral penetration of nanoparticles.
Niu Y; Zhu J; Li Y; Shi H; Gong Y; Li R; Huo Q; Ma T; Liu Y
J Control Release; 2018 May; 277():35-47. PubMed ID: 29545106
[TBL] [Abstract][Full Text] [Related]
9. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
10. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
11. Emerging strategies against tumor-associated fibroblast for improved the penetration of nanoparticle into desmoplastic tumor.
Yunna C; Mengru H; Fengling W; Lei W; Weidong C
Eur J Pharm Biopharm; 2021 Aug; 165():75-83. PubMed ID: 33991610
[TBL] [Abstract][Full Text] [Related]
12. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy.
Shi Y; van der Meel R; Chen X; Lammers T
Theranostics; 2020; 10(17):7921-7924. PubMed ID: 32685029
[TBL] [Abstract][Full Text] [Related]
13. EPR-effect: utilizing size-dependent nanoparticle delivery to solid tumors.
Stylianopoulos T
Ther Deliv; 2013 Apr; 4(4):421-3. PubMed ID: 23557281
[No Abstract] [Full Text] [Related]
14. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines.
Greish K
J Drug Target; 2007; 15(7-8):457-64. PubMed ID: 17671892
[TBL] [Abstract][Full Text] [Related]
15. Drug self-delivery systems for cancer therapy.
Qin SY; Zhang AQ; Cheng SX; Rong L; Zhang XZ
Biomaterials; 2017 Jan; 112():234-247. PubMed ID: 27768976
[TBL] [Abstract][Full Text] [Related]
16. Nanomedicine for the treatment of triple-negative breast cancer.
Kutty RV; Wei Leong DT; Feng SS
Nanomedicine (Lond); 2014 Apr; 9(5):561-4. PubMed ID: 24827837
[No Abstract] [Full Text] [Related]
17. [The development of novel tumor targeting delivery strategy].
Gao HL; Jiang XG
Yao Xue Xue Bao; 2016 Feb; 51(2):272-80. PubMed ID: 29856581
[TBL] [Abstract][Full Text] [Related]
18. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise.
Bharali DJ; Mousa SA
Pharmacol Ther; 2010 Nov; 128(2):324-35. PubMed ID: 20705093
[TBL] [Abstract][Full Text] [Related]
19. The holistic 3M modality of drug delivery nanosystems for cancer therapy.
Sun J; Luo C; Wang Y; He Z
Nanoscale; 2013 Feb; 5(3):845-59. PubMed ID: 23292001
[TBL] [Abstract][Full Text] [Related]
20. Redox Potential and ROS-Mediated Nanomedicines for Improving Cancer Therapy.
Glass SB; Gonzalez-Fajardo L; Beringhs AO; Lu X
Antioxid Redox Signal; 2019 Feb; 30(5):747-761. PubMed ID: 28990403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
